About Marinus Pharmaceuticals

“Our goal at Marinus is to maximize the value of ganaxolone -- a positive allosteric modulator of GABAA -- with a new mechanism of action and various dose forms to treat drug-resistant seizures and neuropsychiatric disorders.”

- Christopher M. Cashman, CEO

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to improving the lives of patients and families suffering from seizures, depression and other neuropsychiatric disorders.  Our lead clinical stage drug candidate, ganaxolone, brings a new GABAA receptor modulating mechanism and an extensive safety database with exhibited anxiolytic, anti-seizure and anesthetic activity.

Marinus is developing three different convenient dose forms of ganaxolone (IV, capsule, and liquid) to maximize the therapeutic reach to adult and pediatric patients in both acute and chronic care settings where there is a mechanistic rationale for ganaxolone to provide a benefit.

Our goal is to maximize the value of ganaxolone as a first-in-class innovative neuropsychiatric therapy with a portfolio of diversified indications. To achieve this goal, we are focused on the following:

  • Targeting underserved and orphan indications where we believe modulating GABAA would provide a therapeutic benefit to patients
  • Developing a range of ganaxolone dose forms for adults and pediatrics for use in acute and chronic care settings
  • Establishing proof-of-concept clinical data in support of progressing to advanced pivotal studies
  • Leveraging and expanding our extensive intellectual property asset base

In addition to our ganaxolone franchise development, we may acquire and develop other drug candidates consistent with our mission, capabilities and planned commercial footprint.

The Marinus Team

The Marinus team is committed to developing new treatment options for patients suffering from epilepsy and neurological disorders.